Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry
Authors:
- 6 December 2025
- journal article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 581, 120775
Abstract
No abstract availableKeywords
Funding Information
- Peking University Shenzhen Hospital
- Shenzhen Science and Technology Innovation Program (JCYJ20240813120000002)
This publication has 20 references indexed in Scilit:
- Multiple myelomaNature Reviews Disease Primers, 2024
- Anti CD38 monoclonal antibodies for multiple myeloma treatmentHuman Vaccines & Immunotherapeutics, 2022
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2021
- Clearing drug interferences in myeloma treatment using mass spectrometryClinical Biochemistry, 2021
- MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteinsClinica Chimica Acta, 2019
- Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal AntibodiesJournal of Proteome Research, 2018
- Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral bloodClinical Biochemistry, 2018
- Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug TreatmentClinical Pharmacokinetics, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014